Canaccord Genuity Starts Harpoon Therapeutics (HARP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Wedbush Starts Harpoon Therapeutics (HARP) at Outperform
March 5, 2019 6:45 AM ESTWedbush analyst Robert Driscoll initiates coverage on Harpoon Therapeutics (NASDAQ: HARP) with a Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.
Shares of Harpoon Therapeutics closed at $17.01 yesterday.
... More